RECOVER
20.11.2023 08:01:28 CET | Business Wire | Press release
On 23-24 November, textile industry experts Recover™, Evlox and Jeanologia will showcase their new recycled denim capsule collection, REICONICS, at Denim Première Vision in Milan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231119049088/en/
(Photo: Jeanologia)
The collection is the result of a collaborative project between the three companies, combining expertise from each specialist business to improve circularity in the denim industry, from fiber to finish.
It aims to inspire and bring value to the industry by creating truly circular products through a process that implements eco-design, transparency, process measurement, traceability, and scalability.
Made from Recover™ recycled cotton fiber and Spanish cotton, the REICONICS collection is GRS certified and is a tribute to the classic denim fabrics that have been successful in past decades.
It includes a range of premium denim fabrics developed by Evlox and a total of 14 final garments that will be exhibited at Premiere Vision Denim. Each piece in the collection displays a variety of finishes generated using technology by Jeanologia, reducing water and energy consumption, and eliminating damaging emissions and discharge.
Just one jacket in the REICONICS collection, using 32% Recover™ recycled fiber and Jeanologia finishing technology, saves up to 760 liters of water; compared to a jacket made with virgin cotton and treated with traditional finishing techniques.
Alfredo Ferre, CEO at Recover™ stated, "Recover™ is proud to be part of the REICONICS collection, a groundbreaking project that will pave the way toward a more sustainable future. Together we are offering brands a pathway to reduce their environmental impact caused by raw material production and waste.”
Francisco Ortega, Evlox R&D Director, also commented, “We are thrilled to implement new models of denim manufacturing, more circular and sustainable with the help of recognized partners such as Recover™ and Jeanologia with whom we have been collaborating for years, this capsule is another milestone in the challenge of making circular fashion accessible to everyone, without compromising the denim heritage”.
Enrique Silla, CEO at Jeanologia stated, “At Jeanologia we are proud to work with Recover™ and Evlox as partners to redefine the future of Blue jeans. REICONICS Collection creates an inflection point where technology, innovation, creativity, circularity, and sustainability are key to success. To achieve the excellent product whilst producing in a responsible and sustainable way.”
If you are interested in learning more about how to reduce the use of virgin materials in denim and reduce environmental impacts, please visit https://recoverfiber.com/newsroom/reiconics-jeanologia-evlox-recover.
ENDS
Images of the REICONICS recycled denim collection can be downloaded here.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Evlox
We are Denimakers since 1846. More than 175 years specialized in manufacturing denim, reinventing a classic, creating new solutions for the world’s most important brands. In Evlox we are passionate about our work, and for this reason we continue leading the way in the sector. With 12 million metres of Premium denim produced every year, more than 500 employees and a commercial presence in 50 countries, Evlox is today synonymous with improvement, innovation, and leadership.
About Jeanologia
Since 1994, Jeanologia’ s mission has been to create an ethical, sustainable, and eco-efficient textile industry. The company collaborates closely with brands, retailers, and their suppliers on their transformative journey. Jeanologia offers disruptive technologies, innovative software, and a new operational model. Their groundbreaking solutions, including laser technology, G2 ozone, Dancing Box, e-flow, and H2Zero, have revolutionized the textile industry, providing limitless design and garment finishing possibilities. These advancements not only reduce costs but also conserve water, energy, and chemicals, ensuring zero pollution.
Today, Jeanologia encourages all textile industry stakeholders to get behind their Mission Zero: dehydrate and detoxify the jean industry. No more water or toxic chemicals used in a single pair of jeans around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231119049088/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom